The Claim

A single intravenous dose of 50 mg or 150 mg of the human monoclonal antibody K1-70TM in adults with Graves' disease causes a sustained reduction in free triiodothyronine and free thyroxine levels, a corresponding increase in thyroid-stimulating hormone, and induces a hypothyroid state in 100% of treated patients within 28 days through direct pharmacodynamic blockade of the thyroid-stimulating hormone receptor.

Source: TSH receptor specific monoclonal autoantibody K1‐70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
45score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

A single intravenous injection of K1-70TM at 50 mg or 150 mg in adults with Graves' disease reduces free triiodothyronine and free thyroxine, increases thyroid-stimulating hormone, and results in hypothyroidism in all treated individuals within 28 days by directly blocking the thyroid-stimulating hormone receptor.

See the scientific wording

A single intravenous dose of 50 mg or 150 mg of the human monoclonal antibody K1-70TM in adults with Graves' disease leads to a sustained reduction in free triiodothyronine and free thyroxine levels and a corresponding increase in thyroid-stimulating hormone, resulting in a hypothyroid state in 100% of treated patients within 28 days, demonstrating direct pharmacodynamic blockade of the thyroid-stimulating hormone receptor.

Why this might work

A specific antibody binds to the thyroid gland's hormone production switch, preventing any natural or abnormal signals from turning it on. Without this signal, the thyroid stops making thyroid hormones. When hormone levels drop, the brain detects the low levels and sends a stronger signal to the thyroid to work harder, but the antibody blocks that signal too. This keeps the thyroid inactive, leading to persistently low hormone levels and high brain signal levels.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: TSH receptor specific monoclonal autoantibody K1‐70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial

    A single shot of this antibody lowered the overactive thyroid hormones in people with Graves' disease and raised the signal that tells the thyroid to slow down, effectively calming the overactive thyroid — just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.